Hemorrhagic cystitis as an unexpected adverse reaction to temozolomide: Case report

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 25, Issue 5, 2002, Pages 513-514

  Islam, Rezwan ^a   Isaacson, Bart J ^a   Zickerman, Philip M ^a   Ratanawong, Chirasakdi ^a   Tipping, Stuart J ^a  

^a MARSHFIELD CLINIC   (United States)

Author keywords

Alkylating agents; Cyclophosphamide; Hematuria; Imidazotetrazines

Indexed keywords

ALKYLATING AGENT; TEMOZOLOMIDE; TETRAZINE DERIVATIVE;

ADULT; ARTICLE; BLOOD BRAIN BARRIER; BONE MARROW SUPPRESSION; BRAIN METASTASIS; BREAST CANCER; CANCER PATIENT; CASE REPORT; CONSTIPATION; FATIGUE; FEMALE; HEADACHE; HEMATURIA; HEMORRHAGIC CYSTITIS; HUMAN; NAUSEA; VOMITING;

ANTINEOPLASTIC AGENTS, ALKYLATING; BRAIN NEOPLASMS; BREAST NEOPLASMS; CYSTITIS; DACARBAZINE; FEMALE; HEMORRHAGE; HUMANS; MIDDLE AGED;

EID: 0036793835     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/00000421-200210000-00018     Document Type: Article

References (17)

1. Franke W, Neumann NJ, Richter-Hintz D, et al. Temozolomide - a promising agent in the therapy of brain metastases in malignant melanoma. Proc ASCO 2000;19:575A.
2. Cox PJ. Cyclophosphamide cystitis - identification of acrolein as the causative agent. Biochem Pharmacol 1979;28:2045-9.
3. 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 1999;5:309-17.
4. Newlands ES, O'Reilly SM, Glaser MG, et al. The Charing Cross Hospital experience with temozolomide in patients with gliomas. Eur J Cancer 1996;32A:2236-41.
5. Meini S, Lecci A, Cucchi P, et al. Inflammation modifies the role of cyclooxygenases in the contractile responses of the rat detrusor smooth muscle to kinin agonists. J Pharmacol Exp Ther 1998;287:137-43.
6. deVries CR, Freiha FS. Hemorrhagic cystitis: a review. J Urol 1990;143:1-9.
7. Brada M, Judson I, Beale P, et al. Phase I dose-escalation and pharmacokinetic study of temozolomide (SCH 52365) for refractory or relapsing malignancies. Br J Cancer 1999;81:1022-30.
8. Britten CD, Rowinsky EK, Baker SD, et al. A phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res 1999;5:1629-37.
9. Hammond LA, Eckardt JR, Baker SD, et al. Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol 1999;17:2604-13.
10. Bower M, Newlands ES, Bleehen NM, et al. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma. Cancer Chemother Pharmacol 1997;40:484-8.
11. 18F]]fluorodeoxyglucose and positron emission tomography: a pilot study following the phase II chemotherapy schedule for temozolomide in recurrent high-grade gliomas. Br J Cancer 2000;82:608-15.
12. Janinis J, Efstathiou E, Panopoulos C, et al. Phase II study of temozolomide in patients with relapsing high grade glioma and poor performance status. Med Oncol 2000;17:106-10.
13. Yung WKA, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. J Clin Oncol 1999;17:2762-71.
14. Yung WKA, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 2000;83:588-93.
15. Middleton MR, Grob JJ, Aaronson N, et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol 2000;18:158-66.
16. Agarwala SS, Kirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist 2000;5:144-51.
17. Ballen KK, Becker P, Levebvre K, et al. Safety and cost of hyperhydration for the prevention of hemorrhagic cystitis in bone marrow transplant recipients. Oncology 1999;57:287-92.